Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?
Chinese Clinical Oncology · 2024
DOI: 10.21037/cco-23-66 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chinese Clinical Oncology, 2024. Verfasst von Benedikt Hoeh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt am Main, Frankfurt am Main, Germany.
Zitieren
APA
Hoeh, B., Chun, F. K. H., & Mandel, P. (2024). Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?. Chinese Clinical Oncology. https://doi.org/10.21037/cco-23-66
Vancouver
Hoeh B, Chun FKH, Mandel P. Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?. Chinese Clinical Oncology. 2024. doi:10.21037/cco-23-66
BibTeX
@article{Hoeh2024,
author = {Hoeh, Benedikt and Chun, Felix K H and Mandel, Philipp},
title = {Disease volume and risk subgroup analyses for darolutamide plus androgen-deprivation therapy and docetaxel in the phase III ARASENS: should triplet therapy become standard of care in certain metastatic hormone-sensitive prostate cancer patients?},
journal = {Chinese Clinical Oncology},
year = {2024},
doi = {10.21037/cco-23-66}
}
EUVIMED